Synaptogenix (NASDAQ:TAOX) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Synaptogenix (NASDAQ:TAOX) from a hold rating to a sell rating in a research report released on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Synaptogenix Price Performance

TAOX opened at $4.13 on Friday. The company has a market cap of $30.77 million, a P/E ratio of -0.20 and a beta of 1.99. The business has a 50-day moving average of $5.31. Synaptogenix has a 1-year low of $1.84 and a 1-year high of $11.98.

Synaptogenix (NASDAQ:TAOX) last posted its quarterly earnings results on Friday, November 14th. The company reported ($1.56) EPS for the quarter. The company had revenue of $2.41 million during the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.